Piergiorgio Malagoli

Learn More
HLA polymorphisms of class I (HLA-A, B, C) of class II (HLA-DR, DQ) and of class III (C4A, C4B, BF) were investigated in 93 Northern Italian patients affected with vitiligo and in 388 controls. Vitiligo patients had significant increases in HLA-A30 (corrected p, pc = 0.0144), Cw6 (pc = 0.0189), DQw3 (pc less than 0.0003) and a significant decrease in C4AQ0(More)
BACKGROUND Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. OBJECTIVE To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. METHODS Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity(More)
BACKGROUND Little is known about the role of the HLA-C*06 allele in the response to psoriasis treatments. OBJECTIVES To confirm the role of HLA-C*06 as a pharmacogenetic marker of response to ustekinumab in a new, large cohort of patients involving four European centres. METHODS In this retrospective multicentre study we reviewed data of 255 patients(More)
We present a 13-year-old girl who came to our attention for an erythematous bruised lesion which appeared spontaneously without any apparent coagulopathy. The history, histology, and positive "skin-test," carried out by subcutaneously injecting autologous erythrocytes obtained from heparinized blood, confirmed the suspected diagnosis of Diamond-Gardner(More)
Topical squaric dibutylester (SADBE) is currently used in Europe to treat alopecia areata in adults. We attempted to determine this drug's effectiveness and convenience in treating children with severe alopecia areata who are psychologically disturbed and resistant to other therapies. Twenty-eight children under 13 years of age who had extensive and(More)
BACKGROUND Psoriasis is characterized by multiple genetic variations. Some of these variations, such as the presence of HLA-Cw6 or TNFAIP3 single-nucleotide polymorphisms (SNPs), have been correlated to the response to biologic treatments. OBJECTIVE The aim of our study was to evaluate the effects of IL12B and IL6 SNPs on the response to ustekinumab. (More)
AIM The aim of this study was to provide practical recommendations for optimizing the use of conventional and biological systemic treatments for moderate-severe chronic plaque psoriasis, particularly in case of transitioning and switching. METHODS A total number of 147 dermatologists from 33 different countries including Italy achieved consensus in(More)
  • 1